We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · September 26, 2020

Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone in Advanced NSCLC Without PD‐L1 Expression

Cancer

 

Additional Info

Cancer
Pembrolizumab Plus Chemotherapy Versus Chemotherapy Alone in Patients With Advanced Non-Small Cell Lung Cancer Without Tumor PD‐L1 Expression: A Pooled Analysis of 3 Randomized Controlled Trials
Cancer 2020 Sep 11;[EPub Ahead of Print], H Borghaei, CJ Langer, L Paz-Ares, D Rodríguez-Abreu, B Halmos, MC Garassino, B Houghton, T Kurata, Y Cheng, J Lin, MC Pietanza, B Piperdi, SM Gadgeel

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading